Utilizing Pathway-Directed Therapy in Multiple Myeloma

home / peer-exchange / utilizing-pathway-directed-therapy-in-multiple-myeloma

A panel of medical experts provide insights to the treatment landscape surrounding multiple myeloma (MM).

Episodes

December 21st 2022EP. 1: Front-line Treatment Management for Patients with Multiple Myeloma (MM)

Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).

December 21st 2022EP. 2: MAIA Study and Subgroup Analysis

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.

January 4th 2023EP. 3: SWOG777 Trial and DRd vs VRd

Medical experts explore the SWOG-S0777 trial and present an overview of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs bortezomib, lenalidomide, and low-dose dexamethasone (VRd).

January 4th 2023EP. 4: Patient Frailty Impacting Multiple Myeloma (MM) Treatment Strategies

Brea C. Lipe, MD, highlights considerations for frail patients when treating for MM.

January 11th 2023EP. 5: Adequate Treatment Response in Transplant-Ineligible MM Patients

Raymond Thertulien, MD, PhD, discusses high-risk factors for patients with MM.

January 11th 2023EP. 6: Utilizing Available Frontline Treatment in MM

Daratumumab can be an effective frontline MM treatment option.

January 18th 2023EP. 7: Clinical Pathways Guiding Treatment Selection in Multiple Myeloma

A panel of experts discuss the value of clinical pathways in MM disease management.

January 18th 2023EP. 8: Clinical Collaboration Driving MM Treatment Pathways

Omar Nadeem, MD, shares perspective on the significance of collaborative care in the MM treatment landscape.

January 25th 2023EP. 9: Providing Incentives for Provider Adherence to MM Pathway

Raymond Thertulien, MD, PhD, highlights provider incentives for adherence to MM treatment pathways.

January 25th 2023EP. 10: Product Preference with NCCN Category 1 Status

Dr Haumschild leads a discussion regarding frontline MM treatment products as categorized by NCCN.

February 1st 2023EP. 11: Updates in NCCN Guidelines of Frontline Treatment for MM

Highlighted are updates in NCCN guidelines for frontline MM treatment strategies.

February 1st 2023EP. 12: Differences in Care Between Academic and Community Settings in Multiple Myeloma

Dr Lipe shares disparities between academic and community practice settings for patients with MM.

February 8th 2023EP. 13: Partnering Academic and Community Settings to Optimize Care for Patients with MM

Dr Nadeem provides community and clinical strategies to treat patients with MM.

February 8th 2023EP. 14: Preferred Treatment Sequencing for Patients with MM

In the final discussion, expert panelists navigate treatment sequencing in MM treatment strategies.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions